Continuous Subcutaneous Apomorphine Infusion Improves Severe Restless Legs Syndrome

Müller, Thomas; Marg, Marion; Rothe, Hartmut; Küchler, Matthias

doi:10.1002/mdc3.12039

Cited by 3 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, PLM and flexor reflex decreased 10 min after the SC administration of 3 mg of apomorphine in a 65year old man, and completely disappeared after 30 min (Paradiso et al, 2002). These encouraging preliminary data support the use of apomorphine (associated with domperidone) as a second-line therapy in patients who failed to respond to conventional RLS drug regimen (Tings et al, 2005;Tribl et al, 2005;Müller et al, 2014).…”

Section: Restless Legs Syndrome (Rls) and Periodic Limb Movements Durmentioning

confidence: 55%

“…Apomorphine was not mentioned in this review. However, five case reports (Reuter et al, 1999;Haba-Rubio et al, 2002;Paradiso et al, 2002;Tings et al, 2005;Müller et al, 2014) and one cases series (Tribl et al, 2005) support its potential interest in treating RLS and/or PLMS, either through acute injections or continuous infusion. Nocturnal apomorphine infusion was evaluated in two RLS patients (46 and 58 years, idiopathic RLS and RLS secondary to PD) with PLMS (not assessed during the study) and…”

Section: Restless Legs Syndrome (Rls) and Periodic Limb Movements Durmentioning

confidence: 99%

“…However, the IV route is not recommended for apomorphine, due to crystal accumulation and hazardous IV thrombotic complications (Manson et al, 2001). Similarly, a persistent (6 months follow-up) beneficial effect of continuous subcutaneous apomorphine infusion therapy (CSAI, 120 mg/day) was reported in an 80-year old patient suffering from RLS and polyneuropathy, without severe side effects (Müller et al, 2014). Haba-Rubio and colleagues studied the effect of an acute low single dose of apomorphine (0.5mg) in nine patients (three men, mean age 49.5 years) with PLMS, including eight with RLS (Haba-Rubio et al, 2003).…”

Section: Restless Legs Syndrome (Rls) and Periodic Limb Movements Durmentioning

confidence: 99%

See 2 more Smart Citations

New tricks for an old dog: A repurposing approach of apomorphine

Auffret

Drapier

Vérin

2019

European Journal of Pharmacology

View full text Add to dashboard Cite

Apomorphine is a 150-year old nonspecific dopaminergic agonist, currently indicated for treating motor fluctuations in Parkinson's disease. At the era of drug repurposing, its pleiotropic biological functions suggest other possible uses. To further explore new therapeutic and diagnostic applications, the available literature up to July 2018 was reviewed using the PubMed and Google Scholar databases. As many of the retrieved articles consisted of case reports and preclinical studies, we adopted a descriptive approach, tackling each area of research in turn, to give a broad overview of the potential of apomorphine. Apomorphine may play a role in neurological diseases like restless legs syndrome, Huntington's chorea, amyotrophic lateral sclerosis, Alzheimer's disease and disorders of consciousness, but also in sexual disorders, neuroleptic malignant(-like) syndrome and cancer. Further work is needed in both basic and clinical research; current developments in novel delivery strategies and apomorphine derivatives are expected to open the way.

show abstract

Section: Restless Legs Syndrome (Rls) and Periodic Limb Movements Durmentioning

confidence: 55%

Section: Restless Legs Syndrome (Rls) and Periodic Limb Movements Durmentioning

confidence: 99%

Section: Restless Legs Syndrome (Rls) and Periodic Limb Movements Durmentioning

confidence: 99%

See 1 more Smart Citation

New tricks for an old dog: A repurposing approach of apomorphine

Auffret

Drapier

Vérin

2019

European Journal of Pharmacology

View full text Add to dashboard Cite

show abstract

“…In clinical practice, dopaminergic drugs appear to exert different effects on sleep, with small doses promoting slow-wave sleep (SWS), rapid eye movement (REM) sleep, and possibly inducing drowsiness; and large doses reducing SWS, REM sleep, and increasing wakefulness [4]. Among them, non-ergot DA can alleviate some sleep disorders in PD patients [5][6][7], while possibly inducing other sleep disorders [8]. Studies have found that the adverse effects of levodopa on sleep may be stronger than DA [9].…”

Section: Introductionmentioning

confidence: 99%

Clinical Manifestations of Subjective Sleep Disorders in Chinese Patients with Parkinson’s Disease and Their Relationship with Dopaminergic Drugs

Wu,

He,

et al. 2023

Eur Neurol

View full text Add to dashboard Cite

Introduction: Sleep disorders are common in Parkinson’s disease (PD) and significantly impact quality of life. Herein, we surveyed the incidence and severity of sleep disorders in Chinese PD patients and observed their relationship with dopaminergic drugs. Methods: We collected the demographic and disease information of 232 PD patients. The incidence and severity of sleep disorders were surveyed with the Parkinson’s disease sleep scale (PDSS) Chinese version. Data on dopaminergic drug intake were collected and converted to levodopa equivalent doses (LED). Results: The average total score of PDSS in 232 patients was 119.3 ± 19.7. There was a significant difference in PDSS scores between groups classified by the Hoehn-Yahr (H&Y) stage, but not between the groups classified by the type of dopaminergic drugs. Stepwise regression analysis revealed that the LED of dopaminergic drugs taken before bedtime (p < 0.00), LED of dopaminergic drugs taken over a 24-h period (p < 0.00), and scores of the Hamilton Rating Scale for Depression (HAMD) (p = 0.01) were determinants of PDSS. Conclusion: Sleep disorders in PD patients may be multifactorial. High dosage of dopaminergic drugs taken prior to sleep, daily total high dosage of dopaminergic drugs, and depression exert negative effects on subjective sleep. The timing and dosage of dopaminergic drugs taken before bedtime should be considered in PD management.

show abstract

Apomorphine

2017

Reactions Weekly

View full text Add to dashboard Cite

Continuous Subcutaneous Apomorphine Infusion Improves Severe Restless Legs Syndrome

Cited by 3 publications

References 5 publications

New tricks for an old dog: A repurposing approach of apomorphine

New tricks for an old dog: A repurposing approach of apomorphine

Clinical Manifestations of Subjective Sleep Disorders in Chinese Patients with Parkinson’s Disease and Their Relationship with Dopaminergic Drugs

Apomorphine

Contact Info

Product

Resources

About